Bharat Biotech

Indian biotechnology company and vaccine manufacturer

Bharat Biotech ▸ Facts ▸ Comments ▸ News ▸ Videos

Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in Hyderabad, engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

0 shares	Share Tweet Save Post Send


BJP Minister Prakash Javadekar says India will be fully vaccinated by December 2021 \| Oneindia News Union Minister, BJP, Ministry of Environment, Forest and Climate Change, Ministry of Information and Broadcasting, Ministry of Heavy Industries and Public Enterprises, Congress leader, Congress MP,.. Credit: Oneindia Duration: 02:01Published 3 weeks ago

Jharkhand Police: ₹ 35 lakh as fine from masses violating Covid norms \| Oneindia News Thousands of people including Covid patients evacuated because of Cyclone Tauktae from Gujarat and Maharashtra; Bharat Biotech said that the company manufactured Covaxin is effective against the.. Credit: Oneindia Duration: 03:39Published on May 16, 2021

Bharat Biotech responds to Delhi's Covaxin plea, says...\| Oneindia News Covaxin's maker Bharat Biotech has refused to supply vaccine doses to Delhi, Deputy Chief Minister Manish Sisodia said today. Cong MP Rahul Gandhi hit out at the centre's push for positivity aid the.. Credit: Oneindia Duration: 03:17Published on May 12, 2021


Chhattisgarh will receive 3.50 lakh doses of Covishield today Health Minister of Chhattisgarh, TS Singh Deo on May 08 said the state government will receive 3.50 lakh doses of Covishield today and the further vaccination will go on with this. "We received 1.50.. Credit: ANI Duration: 01:25Published on May 8, 2021

India receives first lot of Sputnik V vaccine India on May 01 got the first lot of Russia's Sputnik V vaccine. The shipment arrived at the Hyderabad airport where Indian authorities received the first batch of 1.5 lakh doses of the Russia-made.. Credit: ANI Duration: 02:00Published on May 1, 2021

Have asked for 67 lakh doses each from both vaccine manufacturing companies: CM Kejriwal Delhi Chief Minister Arvind Kejriwal informed that Delhi government has asked both vaccine manufacturing companies, Bharat Biotech and Serum Institute of India for 67 lakh doses each in next 3 months... Credit: ANI Duration: 01:50Published on April 30, 2021

Vaccine manufacturers will supply vaccine by May end: Jharkhand Health Minister Jharkhand Health Minister Banna Gupta on April 29 alleged that vaccine manufacturers said that they can deliver the vaccines only by May end. "We have ordered 25 lakh vaccines each from the Serum.. Credit: ANI Duration: 01:44Published on April 29, 2021

After SII, Bharat Biotech reduces Covaxin price; Rs 400 per dose for state govts Bharat Biotech on Thursday announced a cut in price of its COVID-19 vaccine 'Covaxin' it plans to sell to the states to Rs 400 per dose from the earlier Rs 600. This follows a widespread criticism of.. Credit: HT Digital Content Duration: 01:25Published on April 29, 2021

Covid: SII reduces Covishield price, vaccine now at Rs 300 per dose for states Serum Institute of India reduced the vaccine price for the state government from Rs 400 per dose to Rs 300 per dose. SII chairman Adar Poonawalla announced on Twitter a reduction in prices... Credit: HT Digital Content Duration: 01:27Published on April 28, 2021

Phase-3 vaccination depends on availability of doses: Odisha govt Even as the third phase of COVID-19 vaccination, which will cover people between the age group of 18 and 45, is starting from May 01, several states have expressed apprehensions over the availability.. Credit: ANI Duration: 01:26Published on April 27, 2021

Centre asks Serum Institute, Bharat Biotech to lower Covid vaccines’ price The central government on Monday asked the Serum Institute and Bharat Biotech to lower price of their COVID-19 vaccines amid criticism from various states who accused the companies of profiteering.. Credit: HT Digital Content Duration: 01:28Published on April 26, 2021

Assam govt to give free COVID vaccines to everyone from 18-45 years Assam government has procure 2 crore vaccine from Serum Institute of India and Bharat Biotech and will provide free vaccines to everyone from 18 to 45 years of age, informed state Health Minister.. Credit: ANI Duration: 01:40Published on April 21, 2021

You Might Like

Covaxin does not contain newborn calf serum, say Bharat Biotech and govt IndiaTimes - Published 16 hours ago
Fact Check: No newborn calf serum in Covaxin, Health Ministry and Bharat Biotech confirm The final vaccine does not contain newborn calf serum at all as the calf serum is not an ingredient of the final vaccine product, Health Ministry said DNA - Published 16 hours ago
Covaxin does not contain newborn calf serum: Centre busts myths The indigenously developed Covaxin does not contain newborn calf serum, clarified Centre on Wednesday. The statement came in response to some social media posts which the government said have "twisted.. IndiaTimes - Published 17 hours ago

SII, Bharat Biotech seek hike in government price for Covid vaccines Serum Institute of India (SII) and Bharat Biotech (BB) are seeking higher prices for Covid-19 vaccines from the Centre amid concerns that the cost of Covishield and Covaxin shots in private hospitals.. IndiaTimes - Published 1 day ago
Bharat Biotech says Rs 150 per Covaxin dose to government not sustainable The vaccine maker has said that it had to invest over Rs 500 crore at risk from its resources for product development, clinical trials, manufacturing. DNA - Published 2 days ago
Covaxin average price realisation less than Rs 250 per dose: Bharat Biotech IndiaTimes - Published 2 days ago

CISF takes over security of Bharat Biotech plant IndiaTimes - Published 2 days ago
CISF takes over security of Covaxin manufacturer Bharat Biotech's Hyderabad campus IndiaTimes - Published 2 days ago
Covaxin maker Bharat Biotech gets CISF cover of 64 personnel IndiaTimes - Published 2 days ago
Can person with any allergy take COVID-19 shots? Know what experts say Bharat Biotech, the manufacturer of the COVID-19 vaccine said that those who have known allergies to any component of Covaxin should not take the jab. DNA - Published 4 days ago

Committed to data transparency on Covaxin, published 9 papers in 12 months: Bharat Biotech IndiaTimes - Published 5 days ago
Ocugen to seek emergency nod for Covaxin from Health Canada Bharat Biotech’s US partner Ocugen said it will be seeking an emergency use nod for India’s first indigenously developed Covid-19 vaccine Covaxin from the Canadian health authorities. The company.. IndiaTimes - Published 6 days ago
Ocugen to seek full approval for Covaxin in US via BLA instead of EUA Bharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be pursuing the biologics license application.. IndiaTimes - Published 6 days ago	Ocugen to take BLA route for Covaxin in US based on FDA recommendation; seek emergency use nod for Canada Bharat Biotech’s US partner Ocugen has dropped its plans of applying for an emergency use authorisation (EUA) for indigenously developed Covaxin and will be pursuing the biologics license application.. IndiaTimes - Published 6 days ago
Brazil regulator grants GMP certification to Bharat Biotech's Covaxin facilities Less than a week after Brazil’s health regulator green-lighted the “exceptional import” of 4 million doses of Bharat Biotech’s Covid-19 jab Covaxin, it has now granted certification of Good.. IndiaTimes - Published 1 week ago	Bharat Biotech to conduct Covaxin Phase-4 trials to check real-world effectiveness IndiaTimes - Published 1 week ago
Bharat Biotech exec, researcher spar over vaccine-efficacy study IndiaTimes - Published 1 week ago	Covishield produces more antibodies than Covaxin, finds study Covishield, from the Oxford-AstraZeneca stable, is manufactured by the Serum Institute of India in Pune. Covaxin is the indigenously manufactured vaccine by Hyderabad-based Bharat Biotech in.. IndiaTimes - Published 1 week ago
Good immune response from Covishield & Covaxin: Study A ‘real-world’ study of vaccinated healthcare workers has found Covishield and Covaxin could produce a high immune response in up to 95% recipients and prevent serious disease in those infected.. IndiaTimes - Published 1 week ago	Brazil health regulator finally gives green signal for Covaxin imports In a move that paves the way for exports of indigenously developed Covid-19 vaccine Covaxin to Brazil, its health regulator Anvisa (Agência Nacional de Vigilância Sanitária) has finally given the.. IndiaTimes - Published 2 weeks ago
After US market, Bharat Biotech ties up with Ocugen for Covaxin sale in Canada IndiaTimes - Published 2 weeks ago	Covid-19: Government plans 1 crore daily vaccines from middle of July The Centre plans to ramp up vaccination against Covid-19 on a “mission mode”, targeting an average of around 1 crore inoculations per day from around mid-July or August as vaccine supplies are.. IndiaTimes - Published 2 weeks ago
Bharat Biotech to ramp up production of Covaxin to 10-12 crore doses by July-end: Dr NK Arora With ramping up of production capacities, nearly 25 crore 'Made in India' vaccines are expected to be available by August, a senior official has said and noted that it will go a long way in meeting the.. IndiaTimes - Published 2 weeks ago	2.8 crore doses of Covaxin supplied so far, says Centre Bharat Biotech has supplied almost 2.8 crore doses of Covaxin to the Centre as of May 28 morning, a PIB release said on Friday. Of these, about 2.2 crore doses, including wastage, have been consumed by.. IndiaTimes - Published 3 weeks ago
Centre creating 'artificial scarcity' of Covid vaccines to benefit Bharat Biotech, SII: AAP IndiaTimes - Published 3 weeks ago	Covaxin puzzle: 6 crore shots ready, 2 crore given. Where are the rest? The mismatch between reported production numbers of Covid vaccines in India and the level of daily vaccination seems particularly acute in the case of Covaxin. Official data shows 2.1 crore doses of.. IndiaTimes - Published 3 weeks ago
Bharat Biotech files 2 new GMP certification requests with Brazil's Anvisa for Covaxin IndiaTimes - Published 3 weeks ago	ICMR to examine effectiveness of AstraZeneca's Covishield and Bharat Biotech's Covaxin IndiaTimes - Published 3 weeks ago
Covaxin reached 30 cities in 30 days, says Bharat Biotech's co-founder IndiaTimes - Published 3 weeks ago	Bharat Biotech likely to get a pre-qualification approval from WHO by August The company has informed the government that it is currently in the process of submitting documents, particularly regarding validation of one of its manufacturing facilities. It is also.. IndiaTimes - Published 3 weeks ago
Bharat Biotech needs to give more information for emergency use listing, says WHO IndiaTimes - Published 3 weeks ago	WHO says 'more information' required from Bharat Biotech for emergency use listing of Covaxin IndiaTimes - Published 3 weeks ago
Bharat Biotech submitted 90% of documentation to WHO for emergency use listing for Covaxin: Sources IndiaTimes - Published 3 weeks ago	Paediatric trials of Covaxin may begin in June: Bharat Biotech official Bharath Biotech may start clinical trials of its Covid-19 vaccine Covaxin on children from June, a senior official of the vaccine-maker has said. The efficacy of the jab can be improved up to 100%.. IndiaTimes - Published 3 weeks agoAlso reported by •DNA
Bharat Biotech applies for WHO approval, pre-submission meeting soon It will have to now go through 3 more stages--pre-submission meeting, dossier accepted for review and the final status of assessment. DNA - Published 3 weeks ago	Government steps in to expedite WHO approval for Covaxin ToI has learnt that foreign secretary Harsh Shringla will hold a meeting with Bharat Biotech, the manufacturer of Covaxin, on Monday to expedite the process of WHO approval for the indigenously.. IndiaTimes - Published on May 22, 2021
Exclusive: Bharat Biotech's Suchitra Ella confident on vaccine production commitments She assured that Covaxin was proved to be neutralizing the double mutant variant found in India and other variants found abroad. DNA - Published on May 21, 2021	Bharat Biotech targets 1billion/year doses by 2021-end IndiaTimes - Published on May 21, 2021
Bharat Biotech to ramp up Covaxin production to 1 billion doses a year Hyderabad-based Bharat Biotech is planning to scale up the production capacity of its indigenously-developed Covid vaccine — Covaxin — to 1 billion doses per annum by the fourth quarter of 2021.A.. IndiaTimes - Published on May 20, 2021	Covaxin trial for 2-18 yrs age group to begin in 10-12 days, govt says Trial of Bharat Biotech's Covaxin in the 2-18 years age group is likely to begin in the next 10-12 days., a govt official said. The vaccine received DCGI approval for the trials last week. 1.8% of.. IndiaTimes - Published on May 18, 2021
Covaxin effective against India, UK coronavirus strains: Bharat Biotech IndiaTimes - Published on May 16, 2021	Covaxin effectively neutralises all key emerging variants, says study published in Oxford journal Indigenous Covid-19 vaccine Covaxin has been able to neutralise all key emerging variants, including the double mutant B.1.617 and B.1.1.7, which was first identified in India and the UK, its developer.. IndiaTimes - Published on May 16, 2021
Get Bharat Biotech to share vaccine manufacturing tech with other WHO prequalified pharma cos: Ghulam Nabi Azad IndiaTimes - Published on May 15, 2021	Covaxin dispatched to various states like Gujarat, Assam: Bharat Biotech IndiaTimes - Published on May 14, 2021
Centre, Bharat Biotech willing to invite other companies to scale up Covaxin production Amid the reports of coronavirus vaccine shortage from various states, the Central government and Hyderabad-based Bharat Biotech are willing to invite other companies which want to produce COVAXIN in a.. IndiaTimes - Published on May 13, 2021	Bharat Biotech's 50 employees test COVID-19 positive, Joint MD's tweet evokes mixed response on Twitter Suchitra Ella's tweet evoked mixed response from netizens with some questioning the effectiveness while others asked why the staff was not vaccinated. DNA - Published on May 13, 2021
DGCI gives nod for Covaxin Phase II/III trials on 2-18 year olds The Indian drugs regulator, the Drugs Controller General of India (DCGI) has granted its approval to indigenously developed Covid-19 vaccine Covaxin’s developer Bharat Biotech for conducting Phase.. IndiaTimes - Published on May 13, 2021	50 employees of Bharat Biotech test Covid-19 positive; Joint MD's tweet draws bouquets and brickbats IndiaTimes - Published on May 13, 2021
Serum says will raise monthly production to 10 crore doses by August, Bharat Biotech promises 7.8 crore IndiaTimes - Published on May 13, 2021	Covid-19: DCGI approves phase 2, 3 clinical trials of Covaxin on children aged 2 to 18 years The Drugs Controller General of India (DCGI) approved phase 2 and 3 clinical trials of Bharat Biotech's Covaxin vaccine for the age group of 2 to 18 years, the ministry of health and family welfare.. IndiaTimes - Published on May 13, 2021

Bharat Biotech

Indian biotechnology company and vaccine manufacturer

Bharat Biotech ▸ Facts ▸ Comments ▸ News ▸ Videos

You Might Like

Covaxin does not contain newborn calf serum, say Bharat Biotech and govt

Fact Check: No newborn calf serum in Covaxin, Health Ministry and Bharat Biotech confirm

Covaxin does not contain newborn calf serum: Centre busts myths

SII, Bharat Biotech seek hike in government price for Covid vaccines

Bharat Biotech says Rs 150 per Covaxin dose to government not sustainable

Covaxin average price realisation less than Rs 250 per dose: Bharat Biotech

CISF takes over security of Bharat Biotech plant

CISF takes over security of Covaxin manufacturer Bharat Biotech's Hyderabad campus

Covaxin maker Bharat Biotech gets CISF cover of 64 personnel

Can person with any allergy take COVID-19 shots? Know what experts say

Committed to data transparency on Covaxin, published 9 papers in 12 months: Bharat Biotech

Ocugen to seek emergency nod for Covaxin from Health Canada

Ocugen to seek full approval for Covaxin in US via BLA instead of EUA

Ocugen to take BLA route for Covaxin in US based on FDA recommendation; seek emergency use nod for Canada

Brazil regulator grants GMP certification to Bharat Biotech's Covaxin facilities

Bharat Biotech to conduct Covaxin Phase-4 trials to check real-world effectiveness

Bharat Biotech exec, researcher spar over vaccine-efficacy study

Covishield produces more antibodies than Covaxin, finds study

Good immune response from Covishield & Covaxin: Study

Brazil health regulator finally gives green signal for Covaxin imports

After US market, Bharat Biotech ties up with Ocugen for Covaxin sale in Canada

Covid-19: Government plans 1 crore daily vaccines from middle of July

Bharat Biotech to ramp up production of Covaxin to 10-12 crore doses by July-end: Dr NK Arora

2.8 crore doses of Covaxin supplied so far, says Centre

Centre creating 'artificial scarcity' of Covid vaccines to benefit Bharat Biotech, SII: AAP

Covaxin puzzle: 6 crore shots ready, 2 crore given. Where are the rest?

Bharat Biotech files 2 new GMP certification requests with Brazil's Anvisa for Covaxin

ICMR to examine effectiveness of AstraZeneca's Covishield and Bharat Biotech's Covaxin

Covaxin reached 30 cities in 30 days, says Bharat Biotech's co-founder

Bharat Biotech likely to get a pre-qualification approval from WHO by August

Bharat Biotech needs to give more information for emergency use listing, says WHO

WHO says 'more information' required from Bharat Biotech for emergency use listing of Covaxin

Bharat Biotech submitted 90% of documentation to WHO for emergency use listing for Covaxin: Sources

Paediatric trials of Covaxin may begin in June: Bharat Biotech official

Bharat Biotech applies for WHO approval, pre-submission meeting soon

Government steps in to expedite WHO approval for Covaxin

Exclusive: Bharat Biotech's Suchitra Ella confident on vaccine production commitments

Bharat Biotech targets 1billion/year doses by 2021-end

Bharat Biotech to ramp up Covaxin production to 1 billion doses a year

Covaxin trial for 2-18 yrs age group to begin in 10-12 days, govt says

Covaxin effective against India, UK coronavirus strains: Bharat Biotech

Covaxin effectively neutralises all key emerging variants, says study published in Oxford journal

Get Bharat Biotech to share vaccine manufacturing tech with other WHO prequalified pharma cos: Ghulam Nabi Azad

Covaxin dispatched to various states like Gujarat, Assam: Bharat Biotech

Centre, Bharat Biotech willing to invite other companies to scale up Covaxin production

Bharat Biotech's 50 employees test COVID-19 positive, Joint MD's tweet evokes mixed response on Twitter

DGCI gives nod for Covaxin Phase II/III trials on 2-18 year olds

50 employees of Bharat Biotech test Covid-19 positive; Joint MD's tweet draws bouquets and brickbats

Serum says will raise monthly production to 10 crore doses by August, Bharat Biotech promises 7.8 crore

Covid-19: DCGI approves phase 2, 3 clinical trials of Covaxin on children aged 2 to 18 years